The dual-action debate: Does pharmacology matter?

Journal of Clinical Psychiatry

Volumn 65, Issue SUPPL. 17, 2004, Pages 3-4

  Thase, Michael E ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; NORADRENALIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; HUMAN; MAJOR DEPRESSION; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER, MAJOR; HUMANS; NOREPINEPHRINE; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 16644385087     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (12)

1. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder [Revision]. Am J Psychiatry 2000;157(suppl 4):1-45
2. Clinical Practice Guideline Number 5: Depression in Primary Care, vol 2: Treatment of Major Depression. Rockville, Md: US Dept Health Human Services, Agency for Health Care Policy and Research; 1993. AHCPR publication 93-0551
3. Judd LL, Paulus MJ, Schettler PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 2000;157:1501-1504
4. Judd LL. Adverse outcome of subsyndromal and syndromal levels of depressive symptom severity. Psychosom Med 2000;62:472-473
5. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-241
6. Thase ME, Lu Y, Joliat M, et al. Remission in placebo controlled trials of duloxetine with an SSRI comparator [poster]. Presented at the 156th annual meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, Calif
7. Entsuah R, Zhang J. Rates of complete somatic symptom resolution among depressed patients treated with venlafaxine or SSRIs [poster]. Presented at the 26th annual meeting of the Collegium Internationale Neuropsychopharmacologicum; June 20-24, 2004; Paris, France
8. Entsuah R, Zhang J. Rates of complete symptom resolution among patients treated with venlafaxine or SSRIs [poster]. Presented at the 26th annual meeting of the Collegium Internationale Neuropsychopharmacologicum; June 20-24, 2004; Paris, France
9. Entsuah R. Complete remission of individual symptoms of depression: a comparison of venlafaxine, SSRIs, and placebo [poster]. Presented at the 26th annual meeting of the Collegium Internationale Neuropsychopharmacologicum; June 20-24, 2004; Paris, France
10. Goldstein D, Lu IL, Detke M, et al. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 2004; 45:17-28
11. Entsuah R, Derivan A, Kikta D. Early onset of antidepressant action of venlafaxine: pattern analysis in intent-to-treat patients. Clin Ther 1998; 20:517-526
12. Derivan A, Entsuah AR, Kikta D. Venlafaxine: measuring the onset of antidepressant action. Psychopharmacol Bull 1995;31:439-447